Fundraising FoxFrazier Life Sciences — 2017 Investments
5 investments dated 2017 · listed companies and verified rows first · show all
Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
BiotechDigital HealthGrand Rapids, US
Jerry Callahan(Executive Officer)Brian Farmer(Executive Officer)inRobert Baltera(Executive Officer, Director)Howard Dittrich(Executive Officer)
BoardMichael Jandernoa(Director)Mark Olesnavage(Executive Officer)
Board seatDaniel Estes· per SEC Form D
Co-investorsFrazier Healthcare PartnersNovo Holdings
Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.
BiotechWaltham, US
Daniel F. Flynn, Ph.D.(Executive Officer)Oliver Rosen, M.D.(Executive Officer)inThomas Kelly(Executive Officer)Michael Taylor(Executive Officer, Director)in
BoardMichael Ross(Director)Liam Ratcliffe, M.D., Ph.D.(Director)
Co-investorsViking GlobalREDMILEViking Global Investors
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
BoardDan Janney(Director)
Co-investorsAvoro Capital AdvisorsAlta Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.